ConductScience.org, home

Paper33767404

Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT.

Ruggeri L and 19 others. Bone Marrow Transplant, 2021. Cited by 30 papers, by iCite.

Cite this record

ConductScience Library. Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. Papers, record 33767404. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33767404

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT.
PubMed
Journal
Bone Marrow Transplant
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
30
iCite
Relative citation ratio, by iCite
1.77
iCite
Revised in PubMed
2026-10-10
PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ruggeri LLoredanahttps://orcid.org/0000-0002-3804-2551
2Vago LLucahttps://orcid.org/0000-0003-4247-3175
3Eikema DJDiderik-Jan
4de Wreede LCLiesbeth C
5Ciceri FFabio
6Diaz MAMiguel Angel
7Locatelli FFranco
8Jindra PPavelhttps://orcid.org/0000-0002-8415-7069
9Milone GGiuseppehttps://orcid.org/0000-0002-7840-4414
10Diez-Martin JLJosè Luis
11Pérez-Simón JAJose Antonio
12Merluzzi MMara
13Koster LLinda
14van der Werf SSteffie
15van Biezen AAnja
16Toubert AAntoinehttps://orcid.org/0000-0002-7308-7317
17Nagler AArnonhttps://orcid.org/0000-0002-0763-1265
18Chabannon CChristianhttps://orcid.org/0000-0002-3755-4889
19Bonini CChiara
20Velardi AAndrea

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Graft vs Host DiseaseMajor topic
Hematopoietic Stem Cell TransplantationMajor topic
Leukemia, Myeloid, AcuteMajor topic
Animals
Humans
Killer Cells, Natural
Mice
Prospective Studies
Transplantation, Haploidentical

Source PubMed

Download CSV of topics

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128986344NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications.Blood2018https://conductscience.org/library/papers/28986344PubMed
212393440Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor.Blood2002https://conductscience.org/library/papers/12393440PubMed
39780338Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.N Engl J Med1998https://conductscience.org/library/papers/9780338PubMed
411896281Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.Science2002https://conductscience.org/library/papers/11896281PubMed
522918403Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts.Curr Opin Hematol2012https://conductscience.org/library/papers/22918403PubMed
626130705Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.Blood2015https://conductscience.org/library/papers/26130705PubMed
714688377Determinants of antileukemia effects of allogeneic NK cells.J Immunol2004https://conductscience.org/library/papers/14688377PubMed
826256941Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.Biol Blood Marrow Transplant2015https://conductscience.org/library/papers/26256941PubMed
916864058
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.
Biol Blood Marrow Transplant2006https://conductscience.org/library/papers/16864058PubMed
1022949046The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.Nat Rev Clin Oncol2012https://conductscience.org/library/papers/22949046PubMed
1117371948Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.Blood2007https://conductscience.org/library/papers/17371948PubMed
1229793748NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia.Trends Immunol2018https://conductscience.org/library/papers/29793748PubMed
1325769621Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.Blood2015https://conductscience.org/library/papers/25769621PubMed
1410381530Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.Blood1999https://conductscience.org/library/papers/10381530PubMed
1520538804Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.Blood2010https://conductscience.org/library/papers/20538804PubMed
1628588018Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion.Blood2017https://conductscience.org/library/papers/28588018PubMed
1723423745
T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.
J Clin Oncol2013https://conductscience.org/library/papers/23423745PubMed
1826660427Hematopoietic stem cell transplantation for patients with AML in first complete remission.Blood2016https://conductscience.org/library/papers/26660427PubMed
1923165479Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies.Blood2013https://conductscience.org/library/papers/23165479PubMed
2015753458Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.J Clin Oncol2005https://conductscience.org/library/papers/15753458PubMed

Download CSV of references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.

PMIDTitleJournalYearIn PapersSource
42712389Contrasting relapse rate associated with the absence of HLA-A3/A11 in T cell-replete haploidentical transplantation.Front Immunol2026https://conductscience.org/library/papers/42712389PubMed
41603138Chimerism and a framework for clinical practice: A report from the Cellular Therapies Section Coordinating Committee (CTSCC) of Association for Advancement of Blood and Biotherapies (AABB).Transfusion2026https://conductscience.org/library/papers/41603138PubMed
41375063Natural Killer (NK) Cell-Based Therapies Have the Potential to Treat Ovarian Cancer Effectively by Targeting Diverse Tumor Populations and Reducing the Risk of Recurrence.Cancers (Basel)2025https://conductscience.org/library/papers/41375063PubMed
41154342Allogeneic Hematopoietic Stem Cell Transplantation as a Platform to Treat Chemorefractory Acute Myeloid Leukemia in Adult Patients.Cancers (Basel)2025https://conductscience.org/library/papers/41154342PubMed
41008790Influence of Genetic, Dietary, and Environmental Factors on Natural Killer (NK) Cell Biology and Function: Interplay Between NK Cell Activity and Cancer Onset or Progression.Cancers (Basel)2025https://conductscience.org/library/papers/41008790PubMed
40934005Prediction and effect on relapse of natural killer cell alloreactivity based on KIR-HLA interactions in pediatric haploidentical transplantation with anti-thymoglobulin.Front Immunol2025https://conductscience.org/library/papers/40934005PubMed
40710344Natural Killer (NK) Cell Alloreactivity in Haploidentical Stem Cell Transplantation.Cells2025https://conductscience.org/library/papers/40710344PubMed
40317083Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer.Exp Hematol Oncol2025https://conductscience.org/library/papers/40317083PubMed
39229273Human leukocyte antigen evolutionary divergence as a novel risk factor for donor selection in acute lymphoblastic leukemia patients undergoing haploidentical hematopoietic stem cell transplantation.Front Immunol2024https://conductscience.org/library/papers/39229273PubMed
37398651Heterogeneity in functional genetic screens: friend or foe?Front Immunol2023https://conductscience.org/library/papers/37398651PubMed
36774947Effects of immune system cells in GvHD and corresponding therapeutic strategies.Blood Res2023https://conductscience.org/library/papers/36774947PubMed
36675576Human Leucocyte Antigen System and Selection of Unrelated Hematopoietic Stem Cell Donors: Impact of Patient-Donor (Mis)matching and New Challenges with the Current Technologies.J Clin Med2023https://conductscience.org/library/papers/36675576PubMed
36330529Lactate from the tumor microenvironment - A key obstacle in NK cell-based immunotherapies.Front Immunol2022https://conductscience.org/library/papers/36330529PubMed
36231109Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity.Cells2022https://conductscience.org/library/papers/36231109PubMed
35795036T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies: A Comparison Between CD3+/CD19+ and TCRαβ+/CD19+ Depletion Platforms.Front Oncol2022https://conductscience.org/library/papers/35795036PubMed
35740879Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.Biomolecules2022https://conductscience.org/library/papers/35740879PubMed
35642633Harnessing allogeneic NK cells: improving outcomes with tailored donor lymphocyte infusion.J Clin Invest2022https://conductscience.org/library/papers/35642633PubMed
35327405Influence of Fetomaternal Microchimerism on Maternal NK Cell Reactivity against the Child's Leukemic Blasts.Biomedicines2022https://conductscience.org/library/papers/35327405PubMed
35054985A Hot Topic: Cancer Immunotherapy and Natural Killer Cells.Int J Mol Sci2022https://conductscience.org/library/papers/35054985PubMed
35004548T-Cell-Replete Versus ex vivo T-Cell-Depleted Haploidentical Haematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukaemia and Other Haematological Malignancies.Front Pediatr2021https://conductscience.org/library/papers/35004548PubMed

See all 23 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33767404

GET https://conductscience.org/api/papers/v1/33767404/cited_by?page=2